TL1A Inhibitor Pipeline Review

TL1A Inhibitor Pipeline Review

Target: TL1A; TNF-like ligand 1A

Product Category: Antibody; Small Molecule

This product provides basic information on inhibitor candidates in research and development targeting TL1A.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for inhibitor candidates targeting TL1A (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

The superfamily of tumor necrosis factors (TNF) and the TNF-receptor (TNFR) contain many molecules with vital functions in an array of signaling pathways. One of the most important functions include their role in the development and regulation of the immune system. A member of this family, TNF-like cytokine 1A (TL1A), which is encoded by the TNFSF15 gene, is a transmembrane protein that can be found in both membrane-bound or soluble forms. While both of these forms are structurally similar, they have unique effects on immunological function.

TL1A signals by binding to its receptor, death domain receptor 3 (DR3 or TNFFRSFf25). DR3 shares the most significant homology to TNFR1 among all the TNFR proteins in the superfamily. Downstream signaling following TL1A and DR3 binding include mucosal immunity, intestinal homeostasis, and development and maintenance of inflammatory responses, which can greatly affect patients with diseases such as inflammatory bowel disease (IBD).